ArticleFrontiers in nutrition2026
The impact of sarcopenia on short-term efficacy, toxic and adverse reactions, and prognosis in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia (SP) is an important indicator for evaluating the nutritional status of cancer patients, but its impact on short-term efficacy, toxic and adverse reactions, and long-term survival in patients with non-small cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CRT) remains incompletely understood. Methods: Clinical data of 86 newly diagnosed NSCLC patients who were admitted to Bengbu Medical University First Affiliated Hospital from January 2020 to June 2024 were collected. The skeletal muscle index (SMI) was calculated based on computed tomography (CT) images at the mid-vertebral body of L3. Patients were divided into the SP group (46 cases, 53.5%) and the non-sarcopenia group (40 cases, 46.5%). The incidence of adverse events, short-term efficacy (per RECIST 1.1 criteria), 1 and 3-year overall survival (OS), and progression-free survival (PFS) were compared between the two groups. Cox proportional hazards regression model was used to analyze prognostic factors. Results: Follow-up was conducted until July 31, 2025. The objective response rate (ORR) in the sarcopenia group was significantly lower than that in the non-sarcopenia group (56.5 vs. 80.0%, χ Conclusion: SP can reduce the short-term efficacy of CRT and shorten OS in NSCLC patients. It serves as an independent prognostic factor for these patients, providing guidance for formulating clinical treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.